Dale A. Pelligrino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dale A. Pelligrino has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Vetri
Millennium Pain Center, Bloomington, IL, USA
5 shared publications Hao-Liang Xu
5 shared publicationsChanannait Paisansathan
University of Illinois at Chicago
4 shared publicationsHaoliang Xu
University of Illinois at Chicago
3 shared publicationsVerna L. Baughman
Neuroanesthesia Research Laboratory University of Illinois Chicago Illinois USA
3 shared publicationsLizhen Mao
Neuroanesthesia Research Laboratory University of Illinois Chicago Illinois USA
2 shared publications
Latest Publications
- Open Access
- 27 January 2015
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 12 (1) , 1-9
Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage
Subarachnoid hemorrhage (SAH) is a neurological emergency with limited pharmacological treatment options. Inflammation is increasingly recognized as a key pathogenic contributor to brain injury in this condition. In the present study, we examined the neuroprotective effects of the immunomodulatory agent, fingolimod, in rats subjected to SAH. We utilized an endovascular rat perforation model of SAH. Animals were divided into four groups: (1) sham-vehicle; (2) sham-fingolimod; (3) SAH-vehicle; and (4) SAH-fingolimod. Rats received either vehicle solution or fingolimod (0.5 mg/kg) intraperitoneally 3 hours after sham surgery or SAH. A closed cranial window and intravital microscope system was used at 48 hours to assess neuroinflammation, which was represented by rhodamine-6G-labeled leukocyte trafficking in pial venules, and pial arteriolar dilating responses to a variety of vasodilators, including hypercapnia, and topically-applied acetylcholine, adenosine, and S-nitroso-N-acetyl penicillamine. In addition, motor-sensory function was evaluated. Compared to sham-vehicle rats, SAH-vehicle animals displayed a four-times greater increase in pial venular intraluminal leukocyte adhesion. Treatment with fingolimod largely reduced the intravascular leukocyte adhesion. Vehicle-treated SAH animals displayed a significant decrease in pial arteriolar responses to all the vasodilators tested and vascular reactivity was preserved, to a significant degree, in the presence of fingolimod. In addition, neurological scores obtained at 48 hours post-SAH indicated significant neurological deficits in the vehicle-treated group (versus sham-vehicle surgical control). Those deficiencies were partially reduced by fingolimod (P < 0.0001 compared to the vehicle-treated SAH group). Treatment of rats with fingolimod was associated with a marked limitation in the intravascular adhesion of leukocytes to pial venules, preserved pial arteriolar dilating function, and improved neurological outcome in rats subjected to SAH.
- 27 January 2015
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 12 (1) , 1-9
Open AccessProtective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage
Subarachnoid hemorrhage (SAH) is a neurological emergency with limited pharmacological treatment options. Inflammation is increasingly recognized as a key pathogenic contributor to brain injury in this condition. In the present study, we examined the neuroprotective effects of the immunomodulatory agent, fingolimod, in rats subjected to SAH. We utilized an endovascular rat perforation model of SAH. Animals were divided into four groups: (1) sham-vehicle; (2) sham-fingolimod; (3) SAH-vehicle; and (4) SAH-fingolimod. Rats received either vehicle solution or fingolimod (0.5 mg/kg) intraperitoneally 3 hours after sham surgery or SAH. A closed cranial window and intravital microscope system was used at 48 hours to assess neuroinflammation, which was represented by rhodamine-6G-labeled leukocyte trafficking in pial venules, and pial arteriolar dilating responses to a variety of vasodilators, including hypercapnia, and topically-applied acetylcholine, adenosine, and S-nitroso-N-acetyl penicillamine. In addition, motor-sensory function was evaluated. Compared to sham-vehicle rats, SAH-vehicle animals displayed a four-times greater increase in pial venular intraluminal leukocyte adhesion. Treatment with fingolimod largely reduced the intravascular leukocyte adhesion. Vehicle-treated SAH animals displayed a significant decrease in pial arteriolar responses to all the vasodilators tested and vascular reactivity was preserved, to a significant degree, in the presence of fingolimod. In addition, neurological scores obtained at 48 hours post-SAH indicated significant neurological deficits in the vehicle-treated group (versus sham-vehicle surgical control). Those deficiencies were partially reduced by fingolimod (P < 0.0001 compared to the vehicle-treated SAH group). Treatment of rats with fingolimod was associated with a marked limitation in the intravascular adhesion of leukocytes to pial venules, preserved pial arteriolar dilating function, and improved neurological outcome in rats subjected to SAH.
- 12 April 2014
- Published by Springer Nature
- p. 179-199
Closed Cranial Window Applications in the Rat: Studies on Neurovascular Coupling Involving Pial Arterioles and the Glia Limitans
- 12 April 2014
- Published by Springer Nature
- p. 179-199
Closed Cranial Window Applications in the Rat: Studies on Neurovascular Coupling Involving Pial Arterioles and the Glia Limitans
- Open Access
- 11 October 2012
- Published by Wiley in Journal of Neurochemistry
- Vol. 123 (s2) , 116-124
Post‐ischemic vascular adhesion protein‐1 inhibition provides neuroprotection in a rat temporary middle cerebral artery occlusion model
We examined the neuroprotective efficacy associated with post‐ischemic vascular adhesion protein‐1 (VAP‐1) blockade in rats subjected to transient (1 h) middle cerebral artery occlusion (MCAo). We compared saline‐treated control rats to rats treated with a highly selective VAP‐1 inhibitor, LJP‐1586 [Z‐3‐fluoro‐2‐(4‐methoxybenzyl) allylamine hydrochloride]. Initial intraperitoneal LJP‐1586 (or saline control) treatments were delayed until 6 h or 12 h reperfusion. At 72‐h reperfusion, LJP‐1586‐treated rats displayed 51% and 33% smaller infarct volumes, relative to their controls, in the 6‐ and 12‐h treatment groups, respectively. However, only in the 6‐h treatment group was the infarct volume reduction significant (p < 0.05). On the other hand, we observed significantly improved neurologic functions in both 6‐ and 12‐h treatment groups, versus their matched controls (p < 0.05). Also, the effect of 6‐h LJP‐1586 treatment on post‐ischemic leukocyte trafficking in pial venules overlying the ischemic cortex was evaluated using intravital microscopy. These experiments revealed that: 1) LJP‐1586 did not affect intravascular leukocyte (largely neutrophil) adhesion, at least out to 12‐h reperfusion; and 2) the onset of neutrophil extravasation, which occurred between 6–8‐h reperfusion in control rats, was prevented by LJP‐1586‐treatment. In conclusion, in rats subjected to transient MCAo, selective VAP‐1 pharmacologic blockade provided neuroprotection, with a prolonged therapeutic window of 6–12‐h reperfusion.
- 11 October 2012
- Published by Wiley in Journal of Neurochemistry
- Vol. 123 (s2) , 116-124
Open AccessPost‐ischemic vascular adhesion protein‐1 inhibition provides neuroprotection in a rat temporary middle cerebral artery occlusion model
We examined the neuroprotective efficacy associated with post‐ischemic vascular adhesion protein‐1 (VAP‐1) blockade in rats subjected to transient (1 h) middle cerebral artery occlusion (MCAo). We compared saline‐treated control rats to rats treated with a highly selective VAP‐1 inhibitor, LJP‐1586 [Z‐3‐fluoro‐2‐(4‐methoxybenzyl) allylamine hydrochloride]. Initial intraperitoneal LJP‐1586 (or saline control) treatments were delayed until 6 h or 12 h reperfusion. At 72‐h reperfusion, LJP‐1586‐treated rats displayed 51% and 33% smaller infarct volumes, relative to their controls, in the 6‐ and 12‐h treatment groups, respectively. However, only in the 6‐h treatment group was the infarct volume reduction significant (p < 0.05). On the other hand, we observed significantly improved neurologic functions in both 6‐ and 12‐h treatment groups, versus their matched controls (p < 0.05). Also, the effect of 6‐h LJP‐1586 treatment on post‐ischemic leukocyte trafficking in pial venules overlying the ischemic cortex was evaluated using intravital microscopy. These experiments revealed that: 1) LJP‐1586 did not affect intravascular leukocyte (largely neutrophil) adhesion, at least out to 12‐h reperfusion; and 2) the onset of neutrophil extravasation, which occurred between 6–8‐h reperfusion in control rats, was prevented by LJP‐1586‐treatment. In conclusion, in rats subjected to transient MCAo, selective VAP‐1 pharmacologic blockade provided neuroprotection, with a prolonged therapeutic window of 6–12‐h reperfusion.
- 1 April 2011
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 22 (2) , 229-236
Purinergic mechanisms in gliovascular coupling
- 1 April 2011
- Published by Elsevier in Seminars in Cell & Developmental Biology
- Vol. 22 (2) , 229-236
Purinergic mechanisms in gliovascular coupling
- 1 December 2010
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 299 (6) , H2009-H2017
Interactions between adenosine and K+channel-related pathways in the coupling of somatosensory activation and pial arteriolar dilation
Multiple, perhaps interactive, mechanisms participate in the linkage between increased neural activity and cerebral vasodilation. In the present study, we assessed whether neural activation-related pial arteriolar dilation (PAD) involved interactions among adenosine (Ado) A2receptors (A2Rs), large-conductance Ca2+-operated K+(BKCa) channels, and inward rectifier K+(Kir) channels. In rats with closed cranial windows, we monitored sciatic nerve stimulation (SNS)-induced PAD in the absence or presence of pharmacological blockade of A2Rs (ZM-241385), ecto-5′-nucleotidase (α,β-methylene-adenosine diphosphate), BKCachannels (paxilline), and Kirchannels (BaCl2). Individually, these interventions led to 53–66% reductions in SNS-induced PADs. Combined applications of these blockers led to little or no further repression of SNS-induced PADs, suggesting interactions among A2Rs and K+channels. In the absence of SNS, BaCl2blockade of Kirchannels produced 52–80% reductions in Ado and NS-1619 (BKCachannel activator)-induced PADs. In contrast, paxilline blockade of BKCachannels was without effect on dilations elicited by KCl (Kirchannel activator) and Ado suffusions, indicating that Ado- and NS-1619-associated PADs involved Kirchannels. In addition, targeted ablation of the superficial glia limitans was associated with a selective 60–80% loss of NS-1619 responses, suggesting that the BKCachannel participation (and paxilline sensitivity) derived largely from channels within the glia limitans. Additionally, blockade of either PKA or adenylyl cyclase caused markedly attenuated pial arteriolar responses to SNS and, in the absence of SNS, responses to Ado, KCl, and NS-1619. These findings suggested a key, possibly permissive, role for A2R-linked cAMP generation and PKA-induced K+channel phosphorylation in somatosensory activation-evoked PAD.
- 1 December 2010
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 299 (6) , H2009-H2017
Interactions between adenosine and K+channel-related pathways in the coupling of somatosensory activation and pial arteriolar dilation
Multiple, perhaps interactive, mechanisms participate in the linkage between increased neural activity and cerebral vasodilation. In the present study, we assessed whether neural activation-related pial arteriolar dilation (PAD) involved interactions among adenosine (Ado) A2receptors (A2Rs), large-conductance Ca2+-operated K+(BKCa) channels, and inward rectifier K+(Kir) channels. In rats with closed cranial windows, we monitored sciatic nerve stimulation (SNS)-induced PAD in the absence or presence of pharmacological blockade of A2Rs (ZM-241385), ecto-5′-nucleotidase (α,β-methylene-adenosine diphosphate), BKCachannels (paxilline), and Kirchannels (BaCl2). Individually, these interventions led to 53–66% reductions in SNS-induced PADs. Combined applications of these blockers led to little or no further repression of SNS-induced PADs, suggesting interactions among A2Rs and K+channels. In the absence of SNS, BaCl2blockade of Kirchannels produced 52–80% reductions in Ado and NS-1619 (BKCachannel activator)-induced PADs. In contrast, paxilline blockade of BKCachannels was without effect on dilations elicited by KCl (Kirchannel activator) and Ado suffusions, indicating that Ado- and NS-1619-associated PADs involved Kirchannels. In addition, targeted ablation of the superficial glia limitans was associated with a selective 60–80% loss of NS-1619 responses, suggesting that the BKCachannel participation (and paxilline sensitivity) derived largely from channels within the glia limitans. Additionally, blockade of either PKA or adenylyl cyclase caused markedly attenuated pial arteriolar responses to SNS and, in the absence of SNS, responses to Ado, KCl, and NS-1619. These findings suggested a key, possibly permissive, role for A2R-linked cAMP generation and PKA-induced K+channel phosphorylation in somatosensory activation-evoked PAD.
- 22 April 2010
- Published by Elsevier in Brain Research
- Vol. 1342, 118-126
Aldose reductase inhibition ameliorates the detrimental effect of estrogen replacement therapy on neuropathology in diabetic rats subjected to transient forebrain ischemia
- 22 April 2010
- Published by Elsevier in Brain Research
- Vol. 1342, 118-126
Aldose reductase inhibition ameliorates the detrimental effect of estrogen replacement therapy on neuropathology in diabetic rats subjected to transient forebrain ischemia
- Open Access
- 14 April 2010
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 20 (s1) , S51-S62
Caffeine and the Control of Cerebral Hemodynamics
While the influence of caffeine on the regulation of brain perfusion has been the subject of multiple publications, the mechanisms involved in that regulation remain unclear. To some extent, that uncertainty is a function of a complex interplay of pr
- 14 April 2010
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 20 (s1) , S51-S62
Open AccessCaffeine and the Control of Cerebral Hemodynamics
While the influence of caffeine on the regulation of brain perfusion has been the subject of multiple publications, the mechanisms involved in that regulation remain unclear. To some extent, that uncertainty is a function of a complex interplay of pr
- Open Access
- 1 January 2006
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 100 (1) , 3-4
Editorial
Of cerebral blood flow (CBF) control can be traced back to the 1890 publication of Roy and Sherrington entitled "On the regulation of the blood supply of the brain" (6). On the basis of limited experimental evidence, these authors postulated that local changes in cerebral functional activity and perfusion are coupled. However, this concept did not achieve wide acceptance for many years until better tools permitted more in-depth investigations into cerebral hemodynamic regulation. The new information gained from the application of these tools to investigations of CBF regulation not only confirmed the linkage between flow and functional activation alluded to by Roy and Sherrington but also permitted researchers to gain an understanding of CBF responses to changes in circulating levels of the vital metabolic fuels, oxygen and glucose, and responses to metabolic "waste products," like CO 2. Thus dilation of cerebral arteries and increased CBF occurs when blood O 2 or glucose content falls below a certain level or when arterial PCO 2 rises. In the case of O 2 and glucose, the increased perfusion will limit the fall in substrate delivery and possibly prevent neuronal damage. The expansion of our knowledge of CBF regulation, to an important extent, parallels the evolution of the technologies used in studying cerebral hemodynamics. A milestone in the technologic "evolution," and the explosion of information that ensued, relates to publications by Kety and Schmidt in 1945 and 1948 (3, 4). These authors used an ingenious approach, based on the direct Fick principle, that involved inhalation of a diffusible inert gas tracer (N 2 O) in awake humans. The "Kety-Schmidt" technique, for the first time, permitted accurate quantitation of global CBF levels. Many methodologic advances have occurred since that time, a number of which derive from that original work. These include techniques that permit assessments of temporal and regional aspects of CBF regulation. This was covered in a recent editorial (7). More recently, attention has been directed toward studies on the mechanisms of cerebral perfusion regulation at the local, cellular, and molecular levels. Evaluations of "local" factors can involve use of both in vivo and in vitro techniques. The latter includes isolated cerebral arteries and arterioles from different brain sites as well as brain slice preparations, which permit measurements of localized neuronal and astrocytic influences on diameter changes of intraparenchymal arterioles in an environment where the anatomic relationships among neurons, astrocytes, and vascular cells are preserved. In vivo assessments of local factors might involve use of methods that measure regional CBF values [e.g., positron emission tomography (PET) or autoradiography techniques]. Another in vivo model often used in the study of "local" influences on cerebrovascular function is the cranial window technique. This is used to monitor pial arteriolar diameter changes after direct applications of specific pharmacologic or molecular-based agents. Studies of cellular mechanisms often employ cultures of vascular cells (endothelium, smooth muscle) but could also include in vivo preparations employing reductionist strategies (e.g., selective endothelial, astrocyte, or neuronal injury paradigms; pharmacologic interventions directed toward vascular cell-specific targets). Mechanism-driven studies at the molecular level, used in both in vivo and in vitro models, have
- 1 January 2006
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 100 (1) , 3-4
Open AccessEditorial
Of cerebral blood flow (CBF) control can be traced back to the 1890 publication of Roy and Sherrington entitled "On the regulation of the blood supply of the brain" (6). On the basis of limited experimental evidence, these authors postulated that local changes in cerebral functional activity and perfusion are coupled. However, this concept did not achieve wide acceptance for many years until better tools permitted more in-depth investigations into cerebral hemodynamic regulation. The new information gained from the application of these tools to investigations of CBF regulation not only confirmed the linkage between flow and functional activation alluded to by Roy and Sherrington but also permitted researchers to gain an understanding of CBF responses to changes in circulating levels of the vital metabolic fuels, oxygen and glucose, and responses to metabolic "waste products," like CO 2. Thus dilation of cerebral arteries and increased CBF occurs when blood O 2 or glucose content falls below a certain level or when arterial PCO 2 rises. In the case of O 2 and glucose, the increased perfusion will limit the fall in substrate delivery and possibly prevent neuronal damage. The expansion of our knowledge of CBF regulation, to an important extent, parallels the evolution of the technologies used in studying cerebral hemodynamics. A milestone in the technologic "evolution," and the explosion of information that ensued, relates to publications by Kety and Schmidt in 1945 and 1948 (3, 4). These authors used an ingenious approach, based on the direct Fick principle, that involved inhalation of a diffusible inert gas tracer (N 2 O) in awake humans. The "Kety-Schmidt" technique, for the first time, permitted accurate quantitation of global CBF levels. Many methodologic advances have occurred since that time, a number of which derive from that original work. These include techniques that permit assessments of temporal and regional aspects of CBF regulation. This was covered in a recent editorial (7). More recently, attention has been directed toward studies on the mechanisms of cerebral perfusion regulation at the local, cellular, and molecular levels. Evaluations of "local" factors can involve use of both in vivo and in vitro techniques. The latter includes isolated cerebral arteries and arterioles from different brain sites as well as brain slice preparations, which permit measurements of localized neuronal and astrocytic influences on diameter changes of intraparenchymal arterioles in an environment where the anatomic relationships among neurons, astrocytes, and vascular cells are preserved. In vivo assessments of local factors might involve use of methods that measure regional CBF values [e.g., positron emission tomography (PET) or autoradiography techniques]. Another in vivo model often used in the study of "local" influences on cerebrovascular function is the cranial window technique. This is used to monitor pial arteriolar diameter changes after direct applications of specific pharmacologic or molecular-based agents. Studies of cellular mechanisms often employ cultures of vascular cells (endothelium, smooth muscle) but could also include in vivo preparations employing reductionist strategies (e.g., selective endothelial, astrocyte, or neuronal injury paradigms; pharmacologic interventions directed toward vascular cell-specific targets). Mechanism-driven studies at the molecular level, used in both in vivo and in vitro models, have
- Open Access
- 1 December 2004
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 287 (6) , H2501-H2509
cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo
No studies have specifically addressed whether cAMP can influence nitric oxide (NO)/cGMP-induced cerebral vasodilation. In this study, we examined whether cAMP can enhance or reduce NO-induced cerebral vasodilation in vivo via interfering with cGMP efflux or through potentiating phosphodiesterase 5 (PDE5)-mediated cGMP breakdown, respectively, in cerebral vascular smooth muscle cells (CVSMCs). To that end, we evaluated, in male rats, the effects of knockdown [via antisense oligodeoxynucleotide (ODN) applications] of the cGMP efflux protein multidrug resistance protein 5 (MRP5) and PDE5 inhibition on pial arteriolar NO donor [ S-nitroso- N-acetyl penicillamine (SNAP)]-induced dilations in the absence and presence of cAMP elevations via forskolin. Pial arteriolar diameter changes were measured using well-established protocols in anesthetized rats. In control (missense ODN treated) rats, forskolin elicited a leftward shift in the SNAP dose-response curves (∼50% reduction in SNAP EC50). However, in MRP5 knockdown rats, cAMP increases were associated with a substantial reduction in SNAP-induced vasodilations (reflected as a significant 35–50% lower maximal response). In the presence of the PDE5 inhibitor MY-5445, the repression of the NO donor response accompanying forskolin was prevented. These findings suggest that cAMP has opposing effects on NO-stimulated cGMP increases. On the one hand, cAMP limits CVSMC cGMP loss by restricting cGMP efflux. On the other, cAMP appears to enhance PDE5-mediated cGMP breakdown. However, because increased endogenous cAMP seems to potentiate NO/cGMP-induced arteriolar relaxation when MRP5 expression is normal, the effect of cAMP to reduce cGMP efflux appears to predominate over cAMP stimulation of cGMP hydrolysis.
- 1 December 2004
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 287 (6) , H2501-H2509
Open AccesscAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo
No studies have specifically addressed whether cAMP can influence nitric oxide (NO)/cGMP-induced cerebral vasodilation. In this study, we examined whether cAMP can enhance or reduce NO-induced cerebral vasodilation in vivo via interfering with cGMP efflux or through potentiating phosphodiesterase 5 (PDE5)-mediated cGMP breakdown, respectively, in cerebral vascular smooth muscle cells (CVSMCs). To that end, we evaluated, in male rats, the effects of knockdown [via antisense oligodeoxynucleotide (ODN) applications] of the cGMP efflux protein multidrug resistance protein 5 (MRP5) and PDE5 inhibition on pial arteriolar NO donor [ S-nitroso- N-acetyl penicillamine (SNAP)]-induced dilations in the absence and presence of cAMP elevations via forskolin. Pial arteriolar diameter changes were measured using well-established protocols in anesthetized rats. In control (missense ODN treated) rats, forskolin elicited a leftward shift in the SNAP dose-response curves (∼50% reduction in SNAP EC50). However, in MRP5 knockdown rats, cAMP increases were associated with a substantial reduction in SNAP-induced vasodilations (reflected as a significant 35–50% lower maximal response). In the presence of the PDE5 inhibitor MY-5445, the repression of the NO donor response accompanying forskolin was prevented. These findings suggest that cAMP has opposing effects on NO-stimulated cGMP increases. On the one hand, cAMP limits CVSMC cGMP loss by restricting cGMP efflux. On the other, cAMP appears to enhance PDE5-mediated cGMP breakdown. However, because increased endogenous cAMP seems to potentiate NO/cGMP-induced arteriolar relaxation when MRP5 expression is normal, the effect of cAMP to reduce cGMP efflux appears to predominate over cAMP stimulation of cGMP hydrolysis.
- 1 October 2002
- Published by Elsevier in Brain Research
- Vol. 956 (1) , 86-95
Loss of benefit from estrogen replacement therapy in diabetic ovariectomized female rats subjected to transient forebrain ischemia
- 1 October 2002
- Published by Elsevier in Brain Research
- Vol. 956 (1) , 86-95
Loss of benefit from estrogen replacement therapy in diabetic ovariectomized female rats subjected to transient forebrain ischemia